- Video Center
- Social Media
- Media Contacts
Leverkusen, January 21, 2020 – Bayer has been included in the prestigious Gender-Equality Index (GEI) of U.S. financial information service Bloomberg, which marks it out as one of the companies with the strongest and most successful commitment to gender equality anywhere in the world. Only nine other German businesses appear in the highly regarded index, which comprises a total of 325 listed companies spanning 50 different industries across 42 countries.
“Our admission into the Bloomberg Gender-Equality Index is a great acknowledgment of our efforts to ensure an inclusive corporate culture that champions equality,” says Werner Baumann, Chairman of the Board of Management and Labor Director of Bayer AG. “Today, over 31 percent of our management staff throughout the Group are female, which means we’ve increased the proportion of women in management positions by more than ten percentage points in the space of a decade. We’re looking to systematically continue this success with our new diversity strategy,” he adds.
The Bloomberg Gender-Equality Index recognizes listed companies that have demonstrated their commitment to this important goal. Among the criteria for inclusion are the proportion of women in management positions and the talent pipeline, equal pay, an inclusive corporate culture and protection against sexual harassment.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.
Find more information at www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View Download Center